ivarmacitinib   Click here for help

GtoPdb Ligand ID: 11878

Synonyms: example 34 [WO2013091539A1] [4] | SHR-0302 | SHR0302
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Ivarmacitinib (SHR0302) is an oral Janus kinase (JAK) inhibitor, with selectivity for JAK1. It is being investigated for anti-inflammatory potential in auto-inflammatory diseases [2-3,5]. Likely to be administered as the bisulfate salt as outlined in patent WO2014194741A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 140.4
Molecular weight 414.16
XLogP 1.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1nsc(n1)NC(=O)N1C[C@@H]2[C@H](C1)CC(C2)N(c1ncnc2c1cc[nH]2)C
Isomeric SMILES CN(C1C[C@@H]2CN(C[C@@H]2C1)C(=O)Nc1nc(ns1)OC)c1ncnc2c1cc[nH]2
InChI InChI=1S/C18H22N8O2S/c1-25(15-13-3-4-19-14(13)20-9-21-15)12-5-10-7-26(8-11(10)6-12)18(27)23-17-22-16(28-2)24-29-17/h3-4,9-12H,5-8H2,1-2H3,(H,19,20,21)(H,22,23,24,27)/t10-,11+,12?
InChI Key DNBCBAXDWNDRNO-FOSCPWQOSA-N
Immunopharmacology Comments
SHR0302 is a selective JAK1 inhibitor that modulates signaling by IL-4, IL-5, IL-13, IFN-γ, and other cytokine pathways that involved in the pathogenesis of auto-inflammation. It does not cause the neutropenia and anemia that arise from JAK2 inhibition.